Expanding medicinal chemistry space

Drug Discovery Today

Volumn 18, Issue 5-6, 2013, Pages 298-304

  Barker, Andy ^a   Kettle, Jason G ^a   Nowak, Thorsten ^a   Pease, J Elizabeth ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; CELL NUCLEUS RECEPTOR; G PROTEIN COUPLED RECEPTOR; ION CHANNEL; LIPOSOME; NITROGEN; OXYGEN;

ASSAY; BIOLOGY ORIENTED SYNTHESIS; BIOMOLECULAR FLUORESCENCE COMPLEMENTATION ASSAY; BIOSENSOR; CHEMICAL REACTION; COMBINATORIAL CHEMISTRY; DIVERSITY ORIENTED SYNTHESIS; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG INDUSTRY; DRUG PENETRATION; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG TARGETING; ELECTROPHYSIOLOGY; HIGH THROUGHPUT SCREENING; HYDROPHOBICITY; LIPOPHILICITY; MOLECULAR INTERACTION; MOLECULAR WEIGHT; NANOTECHNOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PHYSICAL CHEMISTRY; PROTEIN FRAGMENT COMPLEMENTATION ASSAY; PROTEIN PROTEIN INTERACTION; REVIEW; STEREOCHEMISTRY; SURFACE PLASMON RESONANCE; SYNTHESIS;

BIOLOGICAL AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; HIGH-THROUGHPUT SCREENING ASSAYS; SMALL MOLECULE LIBRARIES; SYSTEMS BIOLOGY;

EID: 84874713456     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.10.008     Document Type: Review

References (70)

1. S. Dandapani, and L.A. Marcaurelle Accessing new chemical space for 'undruggable' targets Nat. Chem. Biol. 6 2010 861 863
2. R.S. Bohacek The art and practice of structure-based drug design: a molecular modeling perspective Med. Res. Rev. 16 1996 3 50
3. J.P. Overington How many drug targets are there? Nat. Rev. Drug Discov. 5 2006 993 996
4. D.H. Drewry, and R. Macarron Enhancements of screening collections to address areas of unmet medical need: an industry perspective Curr. Opin. Chem. Biol. 14 2010 289 298
5. D.J. Payne Drugs for bad bugs: confronting the challenges of antibacterial discovery Nat. Rev. Drug Discov. 6 2007 29 40
6. P. Schmidtke, and X. Barril Understanding and predicting druggability. A high-throughput method for detection of drug binding sites J. Med. Chem. 53 2010 5858 5867
7. R.A. Bauer Expanding the range of druggable targets with natural product-based libraries: an academic perspective Curr. Opin. Chem. Biol. 14 2010 308 314
8. A.T. Bansal, and M.R. Barnes Genomics in drug discovery: the best things come to those who wait Curr. Opin. Drug Discov. Dev. 11 2008 303 310
9. M. Feher, and J.M. Schmidt Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry J. Chem. Inf. Comput. Sci. 43 2003 218 227
10. K. Grabowski, and G. Schneider Properties and architecture of drugs and natural products revisited Curr. Chem. Biol. 1 2007 115 127
11. S. Wetzel Cheminformatic analysis of natural products and their chemical space Chimia 61 2007 355 360
12. M. Lee, and G. Schneider Scaffold architecture and pharmacophoric properties of natural products and trade drugs: application in the design of natural product-based combinatorial libraries J. Comb. Chem. 3 2001 284 289
13. K. Kumar, and H. Waldmann Synthesis of natural product inspired compound collections Angew. Chem. Int. Ed. 48 2009 3224 3242
14. A.L. Harvey Current strategies for drug discovery through natural products Expert Opin. Drug Discov. 5 2010 559 568
15. S.D. Roughley, and A.M. Jordan The medicinal chemist's toolbox: an analysis of reactions used in the pursuit of drug candidates J. Med. Chem. 54 2011 3451 3479
16. F. Lovering Escape from flatland: increasing saturation as an approach to improving clinical success J. Med. Chem. 52 2009 6752 6756
17. F. López-Vallejo Expanding the medicinally relevant chemical space with compound libraries Drug Discov. Today 17 2012 718 726
18. S.L. Schreiber Target-oriented and diversity-oriented organic synthesis in drug discovery Science 287 2000 1964 1969
19. D.R. Spring Diversity-oriented synthesis: a challenge for synthetic chemists Org. Biomol. Chem. 1 2003 3867 3870
20. P. Arya Exploring new chemical space by stereocontrolled diversity-oriented synthesis Chem. Biol. 12 2005 163 180
21. S. Hotha HR22C16: a potent small-molecule probe for the dynamics of cell division Angew. Chem. Int. Ed. Engl. 42 2003 2379 2382
22. P.Y. Ng Synthesis of diverse lactam carboxamides leading to the discovery of a new transcription-factor inhibitor Angew. Chem. Int. Ed. Engl. 46 2007 5352 5355
23. L.F. Peng Syntheses of aminoalcohol-derived macrocycles leading to a small-molecule binder to and inhibitor of Sonic Hedgehog Bioorg. Med. Chem. Lett. 19 2009 6319 6325
24. L.A. Marcaurelle Diversity-oriented synthesis of a cytisine-inspired pyridone library leading to the discovery of novel inhibitors of Bcl-2 Bioorg. Med. Chem. Lett. 19 2009 2500 2503
25. M. Kaiser Biology-inspired synthesis of compound libraries Cell. Mol. Life Sci. 65 2008 1186 1201
26. M.A. Koch Charting biologically relevant chemical space: a structural classification of natural products (SCONP) Proc. Natl. Acad. Sci. U. S. A. 102 2005 17272 17277
27. M.A. Koch Compound library development guided by protein structure similarity clustering and natural product structure Proc. Natl. Acad. Sci. U. S. A. 101 2004 16721 16726
28. S.J. Teague, and A.M. Davis The design of leadlike combinatorial libraries Angew. Chem. Int. Ed. Engl. 38 1999 3743 3748
29. G.M. Rishton Natural products as a robust source of new drugs and drug leads: past successes and present day issues Am. J. Cardiol. 101 2008 43D 49D
30. D.J. Newman, and G.M. Cragg Natural products as sources of new drugs over the last 25 years J. Nat. Prod. 70 2007 461 477
31. M.S. Butler Natural products to drugs: natural product derived compounds in clinical trials Nat. Prod. Rep. 22 2005 162 195
32. Mishra, B.B. and Tiwari, V.K. (2011) Opportunity, challenge and scope of natural products in medicinal chemistry. 1-62 (ISBN: 978-81-308-0448-4), avalable online at: http://www.trnres.com/ebook/uploads/tiwari/T- 1302158431Tiwari%201.pdf
33. J. Hong Role of natural product diversity in chemical biology Curr. Opin. Chem. Biol. 15 2011 350 354
34. D.G.I. Kingston Modern natural products drug discovery and its relevance to biodiversity conservation J. Nat. Prod. 74 2011 496 511
35. S.M. Paul How to improve R&D productivity: the pharmaceutical industry's grand challenge Nat. Rev. Drug Discov. 9 2010 203 214
36. I. Kola, and J. Landis Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3 2004 711 715
37. D.C. Swinney Biochemical mechanisms of new molecular entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and safety Curr. Top. Med. Chem. (Sharjah, United Arab Emirates) 6 2006 461 478
38. D.C. Swinney, and J. Anthony How were new medicines discovered? Nat. Rev. Drug Discov. 10 2011 507 519
39. M. Pineiro-Nunez Lilly's phenotypic drug discovery initiative Abstracts of Papers, 240th ACS National Meeting Boston, MA, United States, August 22-26 2010
40. W. Loging Cheminformatic/bioinformatic analysis of large corporate databases: application to drug repurposing Drug Discov. Today: Ther. Strateg. 8 2011 109 116
41. J. Giacomotto, and L. Ségalat High-throughput screening and small animal models, where are we? Br. J. Pharmacol. 160 2010 204 216
42. K.A. Giuliano Systems cell biology based on high-content screening Methods Enzymol. 414 2006 601 619
43. F. Zanella High content screening: seeing is believing Trends Biotechnol. 28 2010 237 245
44. S. Jain, and P. Heutink From single genes to gene networks: high-throughput-high-content screening for neurological disease Neuron 68 2010 207 217
45. L.M. Mayr, and D. Bojanic Novel trends in high-throughput screening Curr. Opin. Pharmacol. 9 2009 580 588
46. J. Dunlop High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiology Nat. Rev. Drug Discov. 7 2008 358 368
47. P.A. Vidi, and V.J. Watts Fluorescent and bioluminescent protein-fragment complementation assays in the study of G protein-coupled receptor oligomerization and signaling Mol. Pharmacol. 75 2009 733 739
48. T.P. Roddy Mass spectrometric techniques for label-free high-throughput screening in drug discovery Anal. Chem. 79 2007 8207 8213
49. K. Dodgson 100K well screen for a muscarinic receptor using the Epic label-free system-a reflection on the benefits of the label-free approach to screening seven-transmembrane receptors J. Recept. Signal Transduct. Res. 29 2009 163 172
50. B.K. Shoichet Screening in a spirit haunted world Drug Discov. Today 11 2006 607 615
51. L.A. Lor A simple assay for detection of small-molecule redox activity J. Biomol. Screen. 12 2007 881 890
52. B.Y. Feng A high-throughput screen for aggregation-based inhibition in a large compound library J. Med. Chem. 50 2007 2385 2390
53. S.L. McGovern A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening J. Med. Chem. 45 2002 1712 1722
54. P.J. Hajduk, and J. Greer A decade of fragment-based drug design: strategic advances and lessons learned Nat. Rev. Drug Discov. 6 2007 211 219
55. M. Congreve Recent developments in fragment-based drug discovery J. Med. Chem. 51 2008 3661 3680
56. G. Chessari, and A.J. Woodhead From fragment to clinical candidate-a historical perspective Drug Discov. Today 14 2009 668 675
57. S. Perot Druggable pockets and binding site centric chemical space: a paradigm shift in drug discovery Drug Discov. Today 15 2010 656 667
58. R.A. Ward Using protein-ligand docking to assess the chemical tractability of inhibiting a protein target J. Mol. Model. 16 2010 1833 1843 (Online)
59. P.J. Hajduk Druggability indices for protein targets derived from NMR-based screening data J. Med. Chem. 48 2005 2518 2525
60. F.N.B. Edfeldt Fragment screening to predict druggability (ligandability) and lead discovery success Drug Discov. Today 16 2011 284 287
61. Q. Sun Discovery of small molecules that bind to K-Ras and inhibit SOS-mediated activation Angew. Chem. Int. 51 2012 6140 6143
62. T. Maurer Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity Proc. Natl. Acad. Sci. U. S. A. 109 2012 5299 5304
63. C.A. Lipinski Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Deliv. Rev. 23 1997 3 25
64. V. Khanna, and S. Ranganathan Structural diversity of biologically interesting datasets: a scaffold analysis approach J. Cheminf. 3 2011 30
65. J.A. Kritzer Stapled peptides: magic bullets in nature's arsenal Nat. Chem. Biol. 6 2010 566 567
66. A.L. Hopkins Network pharmacology: the next paradigm in drug discovery Nat. Chem. Biol. 4 2008 682 690
67. W. Eberhardt Modulation of mRNA stability as a novel therapeutic approach Pharmacol. Ther. 114 2007 56 73
68. K. Hirata Design of PCR-amplified DNA fragments for in vivo gene delivery: size-dependency on stability and transgene expression J. Pharm. Sci. 96 2007 2251 2261
69. F.J. Dekker Protein structure similarity clustering (PSSC) and natural product structure as inspiration sources for drug development and chemical genomics Curr. Opin. Chem. Biol. 9 2005 232 239
70. S. Betzi Protein-protein interaction inhibition (2P2I): fewer and fewer undruggable targets Comb. Chem. High Throughput Screening 12 2009 968 983